

Please amend the application as follows:¹

IN THE SPECIFICATION

Please delete the paragraph on page 7, lines 7-8,
and replace it with the following paragraph:

Figure 16 shows the complete nucleotide sequence of the
heavy chain from the antibody secreted by K4.1 (SEQ ID NOS 7-
10).

Please delete the paragraph on page 7, lines 9-10,
and replace it with the following paragraph:

Figure 17 shows the complete nucleotide sequence of the
light chain from the antibody secreted by K4.1 (SEQ ID NOS
11-13).

Please delete the paragraph on page 7, lines 11-12,
and replace it with the following paragraph:

Figure 18 shows the complete nucleotide sequence of the
heavy chain from the antibody secreted by D5.1 (SEQ ID NOS
14-17).

¹ An "Appendix of Amendments" is enclosed herewith showing the amendments to the application. In the Appendix, additions are underscored and deletions are bracketed.

Please delete the paragraph on page 7, lines 13-14, and replace it with the following paragraph:

F4 Figure 19 shows the complete nucleotide sequence of the light chain from the antibody secreted by D5.1 (SEQ ID NOS 18-22).

Please delete the paragraph on page 36, lines 10-17, and replace it with the following paragraph:

Both cell lines were known to provide human kappa light chains; for PCR amplification of light chain encoding cDNA, the primers used were HKP1

F3 (5'-CTCTGTGACACTCTCCTGGGAGTT-3') (SEQ ID NO: 1)

for priming from the constant region terminus and two oligos, used in equal amounts to prime from the variable segments:
B3

(5'-CCACCATCAACTGCAAGTCCAGCCA-3') (SEQ ID NO: 2) and B2/B1

(5'-GAAACGACACTCACGCAGTCTCCAGC-3') (SEQ ID NO: 3).

Please delete the paragraph on page 36, lines 18-25, and replace it with the following paragraph:

F6 For amplification of the heavy chain from K4.1 (which contains the murine $\gamma 1$ constant region), the primers were MG-24Vi for the human variable regions: 5'-CAGGTGCAGCTGGAGCAGTCiGG-3' (SEQ ID NO: 4) which, with inosine as shown recognizes the human variable regions V_{H1-2} , V_{H1-3} , V_{H4} and V_{H6} , and from the constant region MG-25 i.e., 5'-

P6
Out

GCACACCGCTGGACAGGGATCCAAGTTTC-3' (SEQ ID NO: 5), which, containing inosine as shown recognizes murine y1, y2A, y2B, and y3.

Please delete the paragraph on page 36, lines 26-30, and replace it with the following paragraph:

P7

For amplification of the heavy chain of the antibody derived from D5.1 (which contains the human μ constant region), MG-24VI was used to prime from the variable and μ P1 (5'-TTTCTTTGTTGCCGTTGGGGTGC-3') (SEQ ID NO: 6) was used as prime from the constant region terminus.

Please insert the Sequence Listing (pages 1-6) submitted herewith at the end of the application after the abstract.

REMARKS

The Examiner states that pending claims 2, 3, 46 and 47² are considered allowable at this time.

² In the Office Action at page 2, the Examiner states that claims 1, 2, 46 and 47 are considered allowable at this time. However, applicants believe the Examiner meant to recite claims 2, 3, 46 and 47 as indicated on the Office Action Summary page. Claim 1 was previously canceled without prejudice in the June 20, 2001 Amendment and Response, and claims 2, 3, 46 and 47 were considered allowable in the October 22, 2002 Office Action.

54

F